Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation (Azylis)

This study has been completed.
European Leukodystrophy Association
Zymenex A/S
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
First received: February 23, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
There is currently no effective treatment for late infantile MLD once clinical symptoms are evident. METAZYM is a recombinant human arylsulfatase A developed for an intravenous ERT for the treatment of late infantile MLD. The overall objective of this study is to evaluate the efficacy and safety of intravenous rhASA treatment in a patient with late infantile MLD who had previously received hematopoietic stem cell transplantation (HCT).

Condition Intervention Phase
Metachromatic Leukodystrophy
Drug: rhARSA
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: and Safety of METAZYM (Recombinant Human Arylsulfatase A or rhASA) for the Treatment of Patients With Late Infantile MLD Who Had Previously Hematopoietic Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Efficacy of METAZYM on peripheral nerve function by electrophysiological studies (motor and sensory nerves conduction velocities) every 6 months; [ Time Frame: every 6 months ] [ Designated as safety issue: No ]
  • Efficacy of METAZYM on peripheral nerve sulfatide storage and demyelination by nerve biopsy at baseline and week 26; [ Time Frame: week 26 ] [ Designated as safety issue: No ]
  • Efficacy of METAZYM on functional capacity by assessing motor function (GMFM) every 6 months [ Time Frame: every 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy of METAZYM on central nervous system involvement by evaluation of cognitive and neurological function, somatosensory and auditory evoked potentials, and brain MRI every 6 months; [ Time Frame: every 6 months ] [ Designated as safety issue: No ]
  • Safety profile of METAZYM by monitoring AE's, vital sign parameters and physical examination findings before each injection, as well as ECGs and routine clinical laboratory tests every 3 months. [ Time Frame: every 3 months ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: October 2008
Study Completion Date: April 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enzyme replacement therapy
intravenous infusion 100U/kg every other week for 18 months
Drug: rhARSA
intravenous infusion 100U/kg every other week for 18 months
Other Names:
  • HGT-1111
  • Metazym

Detailed Description:
Metachromatic Leukodystrophy (MLD) is a rare autosomal recessive disorder caused by the deficiency of the Arylsulfatase A enzyme (ARSA), resulting in accumulation of galactosyl sulfatide (cerebroside sulfate), a major constituent of the myelin sheath. Accumulation of galactosyl sulfatides leads to a progressive degeneration of the white matter in the central and peripheral nervous system (CNS, PNS) and neuronal degeneration. The late infantile form of MLD, which usually is diagnosed in the second year of life, is the most frequent and severe form of the disease. The prognosis is severe, leading to vegetative stage or death within few years after the diagnosis. There is no treatment for patients affected with this early onset form of the disease. In patients with late-onset MLD (juvenile and adult forms), allogeneic hematopoietic stem cell transplantation can stabilize the cerebral demyelination. This treatment is however inefficient in patients with late infantile MLD at a symptomatic stage. The overall objective is to evaluate the efficacy and safety of rhASA treatment in a patient with late infantile MLD who had received HCT at a presymptomatic stage of the disease. Patient will receive rhARSA (100 U/kg) intravenously every other week for a period of 18 months.

Ages Eligible for Study:   6 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities.
  • The patient must have a confirmed diagnosis of MLD as defined by:ARSA activity < 10 nmol/h/mg in leukocytes prior to HCT; Presence of elevated sulfatide in urine prior to HCT
  • The patient must have a residual level of voluntary function (as judged by the investigator), including presence of residual cognitive function (attention, executive and visual functions) as well as the presence of residual voluntary motor function in one upper or lower limb as a minimum.
  • The patient must have an age at the time of screening ≥ 6 months
  • The patient must have had onset of symptoms before the age of 4 years
  • The subject and his/her guardian(s) must have the ability to comply with the clinical protocol
  • The patients' medical record must document that the legal guardian(s) has had independent counselling or a consultation regarding stem cell transplantation in order to assure that the guardian(s) is fully informed regarding the risks and benefits of this alternative

Exclusion Criteria:

Patient will be excluded from this study if they do not meet the specific inclusion criteria, or if any of the following criteria apply:

  • Presence of a gross motor function measure (GMFM < 25)
  • Presence of severe pseudo-bulbar signs (weakness and disco-ordination of tongue and swallowing muscles leading to severe difficulty with swallowing)
  • Spasticity so severe to inhibit transportation
  • Known multiple sulfatase deficiency
  • Presence of major congenital abnormality
  • Presence of known chromosomal abnormality and syndromes affecting psychomotor development
  • Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition
  • Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial
  • Use of any investigational product within 30 days prior to study enrolment or currently enrolled in another study which involves clinical investigations
  • Received ERT with rhASA from any source
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01303146

Department of Pediatric Endocrinology and Neurology, Saint Vincent de Paul Hospital
Paris, France, 75014
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
European Leukodystrophy Association
Zymenex A/S
Study Chair: Patrick Aubourg, MD, PhD Department of Pediatric Endocrinology and Neurology, Saint Vincent de Paul Hospital, Paris
  More Information

Responsible Party: VACHER Yannick, Department of Clinical Research of developpement
ClinicalTrials.gov Identifier: NCT01303146     History of Changes
Other Study ID Numbers: P070805 
Study First Received: February 23, 2011
Last Updated: February 23, 2011
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Metachromatic Leukodystrophy
Enzyme replacement therapy
Allogeneic hematopoietic stem cell transplantation

Additional relevant MeSH terms:
Leukodystrophy, Metachromatic
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Demyelinating Diseases
Genetic Diseases, Inborn
Hereditary Central Nervous System Demyelinating Diseases
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases

ClinicalTrials.gov processed this record on May 26, 2016